Literature DB >> 6289099

Altered supernormality in multiple sclerosis peripheral nerve.

A Eisen, D Paty, M Hoirch.   

Abstract

Supernormality is a regular part of the recovery cycle of nerve. Supernormality was expressed in terms of amplitude, and in 20 control subjects the mean (S2 conditioned/S2 unconditioned) ratio of the median sensory nerve action potential amplitude recorded at the elbow measured 285 +/- 174 (range 119 to 783). A supramaximal conditioning shock was delivered 6 msec in advance of the test pulse. Seventeen (42.5%) of 40 patients with multiple sclerosis (MS) failed to demonstrate supernormality, the (S2 conditioned/S2 unconditioned) ratio being less than 100. This abnormality probably reflects a delay in recovery cycle and is additional evidence implicating peripheral nervous system involvement in multiple sclerosis.

Entities:  

Mesh:

Year:  1982        PMID: 6289099     DOI: 10.1002/mus.880050513

Source DB:  PubMed          Journal:  Muscle Nerve        ISSN: 0148-639X            Impact factor:   3.217


  4 in total

1.  Electrodiagnostic evaluation of peripheral nervous system changes in patients with multiple sclerosis.

Authors:  Hormoz Ayromlou; Hadi Mohammad-Khanli; Mohammad Yazdchi-Marandi; Reza Rikhtegar; Sina Zarrintan; Samad Ej Golzari; Kamyar Ghabili
Journal:  Malays J Med Sci       Date:  2013-07

2.  Blood and CSF Biomarker Dynamics in Multiple Sclerosis: Implications for Data Interpretation.

Authors:  M J Eikelenboom; B M J Uitdehaag; A Petzold
Journal:  Mult Scler Int       Date:  2011-04-14

3.  Strength-duration time constant in peripheral nerve: no abnormality in multiple sclerosis.

Authors:  Gençer Genç; Semai Bek; Tayfun Kasikci; Umit Hidir Ulas; Seref Demirkaya; Zeki Odabasi
Journal:  Mult Scler Int       Date:  2012-05-08

Review 4.  The sad plight of multiple sclerosis research (low on fact, high on fiction): critical data to support it being a neurocristopathy.

Authors:  Peter O Behan; Abhijit Chaudhuri
Journal:  Inflammopharmacology       Date:  2010-09-24       Impact factor: 5.093

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.